BGI Expands Investment in SMRT Sequencing Technology for Its Global Service Business
MENLO PARK, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (Nasdaq:PACB) a pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT®) Technology, and BGI, one of the world’s largest genomics organizations, today announced that BGI has ordered its first Sequel System and plans to purchase additional units in order to further integrate SMRT Sequencing into its global service business. This purchase is a continuation of the commitment to SMRT Sequencing BGI made last year with its purchase of the PacBio® RS II Sequencer.
“We have been very impressed with the SMRT Sequencing technology and our PacBio RS II system. This technology allows BGI to meet the demand for SMRT sequencing services in our bacterial, plant and animal de novo sequencing, transcriptomics sequencing as well as large-scale projects such as the Genome 10K Project,” said Ye Yin, CEO of BGI Genomics. “The addition of the Sequel System enables BGI to increase capacity and offer additional services such as whole genome resequencing and a variety of other long-read-based applications.”
Full article at PACBIO.